MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression

Aim: Immunotherapy and immune checkpoint inhibitors (ICI) have changed cancer care for many patients; however, breast cancers have exhibited minimal response to single agent ICI therapy. There is a significant need to identify novel targets capable of increasing cancer cell immunogenicity and respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Franklin, Derek A., James, Jamaal L., Axelrod, Margaret L., Balko, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556720/
https://www.ncbi.nlm.nih.gov/pubmed/33062958
http://dx.doi.org/10.20517/cdr.2019.109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556720/
https://www.ncbi.nlm.nih.gov/pubmed/33062958
http://dx.doi.org/10.20517/cdr.2019.109

Ejemplares similares